Orion Portfolio Solutions LLC Sells 4,089 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Orion Portfolio Solutions LLC trimmed its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 5.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 68,316 shares of the company’s stock after selling 4,089 shares during the quarter. Orion Portfolio Solutions LLC owned 0.24% of Castle Biosciences worth $1,821,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Castle Biosciences by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after buying an additional 604 shares during the period. Y Intercept Hong Kong Ltd boosted its stake in Castle Biosciences by 3.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company’s stock worth $690,000 after purchasing an additional 845 shares during the period. Truist Financial Corp increased its holdings in Castle Biosciences by 4.6% during the 4th quarter. Truist Financial Corp now owns 21,303 shares of the company’s stock worth $568,000 after purchasing an additional 928 shares in the last quarter. Bailard Inc. raised its stake in shares of Castle Biosciences by 12.5% in the 4th quarter. Bailard Inc. now owns 9,900 shares of the company’s stock valued at $264,000 after purchasing an additional 1,100 shares during the period. Finally, Perkins Capital Management Inc. lifted its holdings in shares of Castle Biosciences by 4.7% in the fourth quarter. Perkins Capital Management Inc. now owns 34,165 shares of the company’s stock valued at $910,000 after purchasing an additional 1,525 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Insider Transactions at Castle Biosciences

In related news, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 2,715 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.62, for a total value of $80,418.30. Following the completion of the sale, the insider now owns 82,047 shares in the company, valued at approximately $2,430,232.14. This trade represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,440 shares of company stock worth $1,081,079 in the last ninety days. Insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CSTL shares. Guggenheim set a $30.00 target price on Castle Biosciences and gave the company a “buy” rating in a research report on Friday, March 28th. Robert W. Baird lifted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Finally, Stephens restated an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a report on Thursday, January 2nd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $20.19 on Thursday. The firm has a market capitalization of $565.46 million, a P/E ratio of 100.96 and a beta of 0.98. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $23.83 and its two-hundred day moving average price is $27.77. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.